课题基金 / 基金详情

EFFICACY AND SAFETY OF ORAL RIDOGREL IN ACTIVE ULCERATIVE COLITIS

EFFICACY AND SAFETY OF ORAL RIDOGREL IN ACTIVE ULCERATIVE COLITIS
口服利多格雷治疗活动性溃疡性结肠炎的疗效和安全性
批准号：
6281700
负责人：
ALAN L. BUCHMAN
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281700
关键词：
clinical research drug screening /evaluation enzyme inhibitors gastrointestinal agents gastrointestinal disorder chemotherapy human subject human therapy evaluation ulcerative colitis

项目摘要

项目成果

ALAN L. BUCHMAN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ulcerative colitis (UC) is a chronic inflammatory condition involving the colon. Patients have abnormally increased thromboxane A2 (TXA2) production in their rectal mucosa, and in intestinal and peripheral blood mononuclear cells. Thromboxanes have proinflammatory effects. Ridogrel specifically inhibits the enzyme thromboxane synthetase and is accompanied by improvement in clinical disease activity in patients with active UC. This study will determine the safety and efficacy of low dose ridogrel for treatment of active UC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE